Skip to content

Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2

Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02867371
Acronym
EAST2
Enrollment
166
Registered
2016-08-15
Start date
2016-08-31
Completion date
2018-12-31
Last updated
2019-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs. This study is being conducted to confirm the performance of the Archimedes System in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer or metastatic disease. Navigation to and sampling of the patient's lung cancer tumor is conducted.

Interventions

The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs

Sponsors

Broncus Medical Inc
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age 21-75 years at screening 2. Highly suspicious pulmonary nodule(s), defined as distinct nodule with a diameter of ≥8mm in its largest dimension 3. No known endobronchial tumor 4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE. 5. Willing to participate in all aspects of study protocol for duration of study 6. Able to understand study requirements 7. Subject or legally authorized representative signs study-related informed consent document

Exclusion criteria

1. Any contraindication to bronchoscopy, for example: 1. Untreatable life-threatening arrhythmias 2. Inability to adequately oxygenate the patient during the procedure 3. Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated) 4. Recent myocardial infarction 5. Previously diagnosed high-grade tracheal obstruction 6. Uncorrectable coagulopathy 2. Known coagulopathy 3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3 4. History of major bleeding with bronchoscopy 5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram 6. Moderate-to-severe pulmonary fibrosis 7. Severe emphysema or COPD: additional testing and PI consent is required 8. Bullae \>5 cm located in vicinity of target nodule or tunnel 9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: 1. ASA class \> 3 2. \> stage 3 heart failure 3. severe cachexia 4. severe respiratory insufficiency or hypoxia 10. Ongoing systemic infection 11. Contraindication to general anesthesia 12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure 13. Participation in any other study in last 30 days 14. Prior thoracic surgery on the same side of the lung as the SPN. 15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study. 16. Life expectancy of less than one year. 17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy 18. Prior radiation therapy treatment in the target lobe

Design outcomes

Primary

MeasureTime frameDescription
Proportion of biopsies yielding tissue sufficient for diagnosisUp to 1 yearThe number of nodules with at least one biopsy sufficient for a definitive tissue diagnosis divided by the number of nodules sampled by the Archimedes System.

Secondary

MeasureTime frameDescription
Procedure planning timeUp to 1 yearThe time from selecting the patient CT until the tunnel path has been selected, reviewed and exported
Nodule access timeUp to 1 yearThe time from the start of navigation until the sheath has been placed at the first biopsy target.
Fluoroscopy timeUp to 1 yearThe total fluoroscopy time from the start of fused-fluoroscopic navigational guidance to the time the devices are removed from the point of entry.
Patient registration timeUp to 1 yearThe total time it takes to correlate the patient's position via fluoroscopy with the navigational guidance system.

Countries

China, Germany, Hong Kong, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026